IGF2 and urinary bladder carcinoma: In addition, abnormal signal transduction and/or promoter activation was reported as a major mechanism for the IGF2 overexpression in a variety of tumors including bladder carcinoma, hepatocellular carcinoma, breast cancer, ovarian cancer and prostate cancer [19-22].